PDMP

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: PDMP
• 英文别名: 1-phenyl-2-decanoylamino-3-morpholino-1-propanol；D,L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol；L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol；N-(1-hydroxy-3-morpholin-4-yl-1-phenylpropan-2-yl)decanamide
• 化学式: C₂₃H₃₈N₂O₃
• 分子量: 390.566
• InChiKey: UYNCFCUHRNOSCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  28
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  61.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS<br/>[FR] NOUVEAUX ANALOGUES SYNTHÉTIQUES DE SPHINGOLIPIDES
  申请人：YISSUM RES DEV CO

  公开号：WO2009060457A1

  公开（公告）日：2009-05-14

  The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent.

  本发明提供了新的鞘氨醇类似物，表示为式（II）的化合物。这些新颖的类似物表现出显著的抗癌效果，因此被作为治疗细胞增殖性疾病、神经退行性疾病、与代谢相关的疾病、传染病和免疫相关疾病的药物组合物。该发明还提供了将式（II）的新颖鞘氨醇类似物与额外治疗剂结合的联合组合物和配套工具。
• [EN] CONJUGATE<br/>[FR] CONJUGUÉ
  申请人：GLYKOS BIOMEDICAL OY

  公开号：WO2019243672A1

  公开（公告）日：2019-12-26

  A conjugate is disclosed. The conjugate may comprise a targeting unit for delivery to a tumour, and a glycosylation inhibitor for inhibiting glycosylation in the tumour, thereby decreasing the immunosuppressive activity of the tumour. The glycosylation inhibitor may be conjugated to the targeting unit.

  揭示了一种共轭物。该共轭物可能包括用于传递至肿瘤的靶向单元，以及用于抑制肿瘤中的糖基化的糖基化抑制剂，从而降低肿瘤的免疫抑制活性。糖基化抑制剂可以与靶向单元结合。
• [EN] BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME<br/>[FR] COMPOSÉS BICYCLIQUES ET PROCÉDÉS DESTINÉS À LEUR UTILISATION DANS LE TRAITEMENT DU SYNDROME DE PITT HOPKINS
  申请人：NEUREN PHARMACEUTICALS LTD

  公开号：WO2021080646A1

  公开（公告）日：2021-04-29

  Embodiments of this invention provide compounds, compositions, methods, and uses for therapeutic diketopiperazines, including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat Pitt Hopkins Syndrome and symptoms thereof, as well as manufacture of compositions, medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.

  该发明的实施例提供了治疗二酮哌啶类化合物、组合物、方法和用途，包括环状G-2-丙烯基脯氨酸和其他环状甘氨酰脯氨酸化合物，用于治疗皮特-霍普金斯综合征及其症状，以及制备包括片剂、胶囊、液体配方、凝胶、注射溶液和其他适用于治疗此类疾病的组合物、药物。
• [EN] PYRIDINE INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE AND THERAPEUTIC METHODS USING THE SAME<br/>[FR] INHIBITEURS PYRIDINE DE LA GLUCOSYLCÉRAMIDE SYNTHASE ET PROCÉDÉS THÉRAPEUTIQUES LES UTILISANT
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2021221953A1

  公开（公告）日：2021-11-04

  Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed.

  葡糖基鞘氨醇合成酶抑制剂和含有该抑制剂的组合物被揭示。还揭示了在治疗疾病和病况中使用葡糖基鞘氨醇合成酶抑制剂的方法，其中抑制葡糖基鞘氨醇合成酶提供益处，如高雪氏病和法布瑞氏病。
• GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
  申请人：The Regents of The University of Michigan

  公开号：US20130095089A1

  公开（公告）日：2013-04-18

  Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed.

  葡糖基鞘氨醇合成酶抑制剂和含有该抑制剂的组合物被揭示。还揭示了在治疗疾病和病况中使用葡糖基鞘氨醇合成酶抑制剂的方法，其中抑制葡糖基鞘氨醇合成酶提供益处，如高雪氏病和法布瑞氏病。